Alantra advises Bridgepoint on the acquisition of PharmaZell Group
ServiceM&A; Debt Advisory
Frankfurt – Alantra, the independent global mid-market investment banking, asset management and portfolio advisory firm, today announced it has advised Bridgepoint on the acquisition of PharmaZell, a leading independent manufacturer of niche active pharmaceutical ingredients (APIs), from DPE Deutsche Private Equity and Maxburg Capital Partners.
PharmaZell is a market leader in the highly resilient and specialty API market where it has a diversified portfolio of over 70 APIs and enjoys leading industry positions in several products that treat respiratory, inflammatory and liver diseases driven by changing lifestyle habits. Many of the Company’s products require special handling procedures and/or technologies. Headquartered in Raubling (near Munich), PharmaZell operates four state-of-the-art production and R&D sites in Germany, Italy and India with over 900 employees globally.
Carsten Kratz, Senior Partner at Bridgepoint noted: “PharmaZell represents an exciting opportunity to invest in a robust platform with an experienced management team and a high-quality customer base in the growing and non-cyclical pharma market. With a strong track record of growth, the company also offers the prospect of further new products and with Bridgepoint will have the resources and reach to further develop selective acquisition opportunities. Many thanks to the Alantra team which provided great support in all facets throughout this transaction.”
Christopher Brackmann, Co-Head DACH region at Bridgepoint highlighted: “The Alantra team had a significant impact on securing the deal for Bridgepoint and we were very pleased with both M&A and Debt Advisory services.”
Wolfram Schmerl, Managing Partner at the Frankfurt office of Alantra, added: “It was a great pleasure to support Bridgepoint on this exciting transaction. PharmaZell has developed into a leading niche specialty API provider in a market with strong growth prospects driven by mega trends in emerging markets such as increase of healthcare standards and increasing drug consumption.”
Jan 2021Sell-side advisoryJan 2021SECTOR HealthcareService M&A
Dec 2020Debt financingValue €50 millionDec 2020SECTOR HealthcareService Debt AdvisoryValue €50 million
Nov 2020Buy-side advisoryNov 2020SECTOR HealthcareService M&A
Oct 2020Buy-side advisoryOct 2020SECTOR HealthcareService M&A